www.fdanews.com/articles/88249-antigenics-announces-expansion-of-its-license-and-supply-agreement-with-glaxosmithkline-biologicals-for-qs-21-stimulon
ANTIGENICS ANNOUNCES EXPANSION OF ITS LICENSE AND SUPPLY AGREEMENT WITH GLAXOSMITHKLINE BIOLOGICALS FOR QS-21 STIMULON
July 10, 2006
Antigenics Inc. announced that the company has signed expanded license and supply agreements for the use of QS-21 Stimulon adjuvant
with GlaxoSmithKline Biologicals, a vaccine division of GlaxoSmithKline (GSK). QS-21 is a key component included in several of GSK's proprietary adjuvant systems.
A number of GSK's vaccine candidates currently under development are formulated
with GSK's proprietary adjuvant systems containing QS-21.
PipelineReview